次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares has been operating for ten years and has over 115 employees in the UK and 5 employees in Zurich.
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※SOSEI：Heptares、研究施設を英国ケンブリッジへ移転することを発表。更なる成長戦略の推進にむけて、Granta Parkに最先端研究開発施設を開設。The Steinmetz Buildingと呼ばれる予定。(6/20)
※ClinicalTrials.gov: A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects. (6/19update, 6/21up)
※Innovate UK transactions over £25,000: Department of Business Innovation & Skills: Grant Expense, Heptares Therapeutics Ltd, 2017/5/11: £102,286.40. (6/21update)
※日本特許(JITSUBO)：新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物 (6/21公開)
※EndPoints: A growing Heptares will continue its recent expansion in the UK by relocating to Granta Park, Cambridge, UK which will house its UK R&D team in 2018. They plan to have 130 employees on site. (6/22)
※Schlieren(Zurich) Press Releases: Yesterday the city welcomed companies, which moved to Schlieren: The Heptares Therapeutics, which belongs to the Japanese Sosei Group. 6 employees. (6/22)
※University of Glasgow: Job Details (Closing: 23 July 2017): "Research Associate": COLLABORATIVE RESEARCH AGREEMENT with Heptares Therapeutics Limited. (6/23)
※ClinicalTrials.gov: Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects (HTL0018318). "Estimated Study Completion: August 15, 2017" (6/23update, 6/26up)
※SOSEI：JITSUBO事業所移転。今後の更なる業務の拡大を図るべく、神奈川県横浜市ライフサイエンス研究センターへ移転し、業務を開始。(6/26)
※米国特許：CGRP Receptor Antagonists. (6/27公開)
※SOSEI：Heptares、ORBITイニシアチブ、ニューヨーク大学医学部と新たな創薬研究開発を開始。共同研究条件下で、初期研究段階プログラムに共同出資予定。(6/28)
※SOSEI：Heptaresとペプチドリーム、炎症性疾患に対する治療薬の研究開発・商業化を目指した戦略的提携契約を締結。(6/29)
※米国特許出願：Piperidin-1 -YL and Azepin-1 -YL Carboxylates as Muscarinic M4 Receptor Agonists. (6/29公開)
※SOSEI：ストック・オプション(新株予約権)の発行内容確定に関するお知らせ。国内：16名70個、海外：103名254個。(6/30)
※SOSEI：株式報酬型ストック・オプション(新株予約権)の発行内容確定に関するお知らせ。国内：2名240個、海外：10名731個。(6/30)
※HeptaresTL: Heptares participating in BigBangFair hosted by AngliaRuskin this week. Anglia Ruskin is a global University with campuses in Cambridge. (6/30)
・・・
※SOSEI平成29年3月期 株主通信：6月下旬予定
※Heptares: We are currently recruiting a Lab Support Technician to join our Operations team GPCR. (7/6 Recruiting End)
※MRC LMB: In celebration of the 10th Anniversary of the founding of Heptares Therapeutics: 7/13 10.00am - 5.30pm.
(Speakers: Fiona Marshall, Malcolm Weir, Chris Tate, Richard Henderson, Gebhard Schertler, Andreas Plückthun, Rob Cooke, Jon Mason, Tim Tasker, Miles Congreve.)
※Heptares: We are currently seeking an experienced Bioinformatician to work with scientists internally and externally across a range of disciplines to advance both our platform technology and our pipeline of new medicines. (7/14 Recruiting End)
※Heptares: We are currently seeking an experienced leader for our computational chemistry group, which is central to our structure-based design efforts, with the motivation and leadership skills to join a world class team at Heptares. (7/14 Recruiting End)
※Novartis Q2 2017 Results: Jul 18, 2017
※Heptares: We are seeking a highly experienced Discovery DMPK leader to influence project direction, and provide strategic and scientific DMPK leadership across the Heptares portfolio. (7/19 Recruiting End)
※Heptares: We are seeking a DMPK Scientist with at least graduate level academic qualifications to join our expanding company and support an exciting and diverse portfolio of small molecule and biological projects. (7/19 Recruiting End)
※AstraZeneca H1 and Q2 2017 Results: Jul 27, 2017
・・・
SOSEIの成長相場の動向：
・Technical Analysis Charts (Day) (Week): ttp://www.4-traders.com/SOSEI-GROUP-CORPORATION-6814799/charts/&applet_mode=statique
次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares has been operating for ten years and has over 115 employees in the UK and 5 employees in Zurich.
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※SOSEI：Heptares、研究施設を英国ケンブリッジへ移転することを発表。更なる成長戦略の推進にむけて、Granta Parkに最先端研究開発施設を開設。The Steinmetz Buildingと呼ばれる予定。(6/20)
※ClinicalTrials.gov: A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects. (6/19update, 6/21up)
※Innovate UK transactions over £25,000: Department of Business Innovation & Skills: Grant Expense, Heptares Therapeutics Ltd, 2017/5/11: £102,286.40. (6/21update)
※日本特許(JITSUBO)：新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物 (6/21公開)
※EndPoints: A growing Heptares will continue its recent expansion in the UK by relocating to Granta Park, Cambridge, UK which will house its UK R&D team in 2018. They plan to have 130 employees on site. (6/22)
※Schlieren(Zurich) Press Releases: Yesterday the city welcomed companies, which moved to Schlieren: The Heptares Therapeutics, which belongs to the Japanese Sosei Group. 6 employees. (6/22)
※University of Glasgow: Job Details (Closing: 23 July 2017): "Research Associate": COLLABORATIVE RESEARCH AGREEMENT with Heptares Therapeutics Limited. (6/23)
※ClinicalTrials.gov: Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects (HTL0018318). "Estimated Study Completion: August 15, 2017" (6/23update, 6/26up)
※SOSEI：JITSUBO事業所移転。今後の更なる業務の拡大を図るべく、神奈川県横浜市ライフサイエンス研究センターへ移転し、業務を開始。(6/26)
※米国特許：CGRP Receptor Antagonists. (6/27公開)
※SOSEI：Heptares、ORBITイニシアチブ、ニューヨーク大学医学部と新たな創薬研究開発を開始。共同研究条件下で、初期研究段階プログラムに共同出資予定。(6/28)
※SOSEI：Heptaresとペプチドリーム、炎症性疾患に対する治療薬の研究開発・商業化を目指した戦略的提携契約を締結。(6/29)
※米国特許出願：Piperidin-1 -YL and Azepin-1 -YL Carboxylates as Muscarinic M4 Receptor Agonists. (6/29公開)
※SOSEI：ストック・オプション(新株予約権)の発行内容確定に関するお知らせ。国内：16名70個、海外：103名254個。(6/30)
※SOSEI：株式報酬型ストック・オプション(新株予約権)の発行内容確定に関するお知らせ。国内：2名240個、海外：10名731個。(6/30)
※HeptaresTL: Heptares participating in BigBangFair hosted by AngliaRuskin this week. Anglia Ruskin is a global University with campuses in Cambridge. (6/30)
・・・
※SOSEI平成29年3月期 株主通信：6月下旬予定
※Heptares: We are currently recruiting a Lab Support Technician to join our Operations team GPCR. (7/6 Recruiting End)
※MRC LMB: In celebration of the 10th Anniversary of the founding of Heptares Therapeutics: 7/13 10.00am - 5.30pm.
(Speakers: Fiona Marshall, Malcolm Weir, Chris Tate, Richard Henderson, Gebhard Schertler, Andreas Plückthun, Rob Cooke, Jon Mason, Tim Tasker, Miles Congreve.)
※Heptares: We are currently seeking an experienced Bioinformatician to work with scientists internally and externally across a range of disciplines to advance both our platform technology and our pipeline of new medicines. (7/14 Recruiting End)
※Heptares: We are currently seeking an experienced leader for our computational chemistry group, which is central to our structure-based design efforts, with the motivation and leadership skills to join a world class team at Heptares. (7/14 Recruiting End)
※Novartis Q2 2017 Results: Jul 18, 2017
※Heptares: We are seeking a highly experienced Discovery DMPK leader to influence project direction, and provide strategic and scientific DMPK leadership across the Heptares portfolio. (7/19 Recruiting End)
※Heptares: We are seeking a DMPK Scientist with at least graduate level academic qualifications to join our expanding company and support an exciting and diverse portfolio of small molecule and biological projects. (7/19 Recruiting End)
※AstraZeneca H1 and Q2 2017 Results: Jul 27, 2017
・・・
SOSEIの成長相場の動向：
・Technical Analysis Charts (Day) (Week): ttp://www.4-traders.com/SOSEI-GROUP-CORPORATION-6814799/charts/&applet_mode=statique
順調に躍進成長。R&D等の拡充・進捗や中長期成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。